Wikipedia

Ulf Landmesser

Ulf Landmesser (24 November 1970 in Dresden) is a German specialist for cardiology and internal medicine. He is professor at the Institute for Health Research in Berlin and Head of the Medical Clinic of Cardiology at the Charité in Berlin. Landmesser is known for his work on coronary interventions and modern methods of catheter-based heart valve therapy.[1]

Biography

edit

From 1990 until 1997 Landmesser studied human medicine at the Hannover Medical School, the University of Connecticut in Farmington (USA) and the National Heart & Lung Institute in London; he specialised in internal medicine and cardiology at the Medical School of Hannover. In 2000–2001 he performed a post-doctoral fellowship at the Department of Cardiology at the Emory University School of Medicine, Atlanta (USA) as a scholar of the Alexander von Humboldt Foundation. Landmesser returned to Hannover and qualified as lecturer on the subject of Oxidative stress and endothelial dysfunction in cardiovascular diseases. When his specialist medical training in cardiology and internal medicine was acknowledged, he first had been working in Hannover until he started his employment as senior physician at the University Hospital of Zürich. In 2010 he was appointed professor by the University of Zürich. In 2010 he became head of Acute Cardiology and in 2012 deputy head of the Department of Cardiology at the University Hospital of Zürich. Since 2014 Landmesser has acted as chairman of the Department of Cardiology at the Charité in Berlin.[2] Furthermore, from 2012 to 2014 he was visiting professor at the University College London and since 2009 has been a deputy editor of the European Heart Journal.

Scientific contribution

edit

Landmesser's research examines mechanisms leading to coronary disease and in particular to myocardial infarction as well as novel catheter-based diagnostic and therapeutic procedures of cardiovascular medicine. The research group of Landmesser characterizes vascular function and the role of lipids in coronary disease and could show, that high-density lipoprotein (HDL) loses important vasoprotective properties in patients with coronary disease or chronic kidney disease, that can help to explain why raising of HDL-C was not effective in reducing cardiovascular risk in several recent large clinical trials.[3][4][5][6][7] Landmesser and his team validated novel high-resolution catheter-based imaging methods for coronary arteries.[8] and examined novel catheter-based approaches of stroke prevention.[9][10][11] Professor Landmesser is active in the task force of the European Society of Cardiology establishing European Guidelines for the treatment of coronary disease.[12][13]

Awards

edit

In 1999 the Swiss Society for Cardiology awarded Landmesser with the "Young Investigator Award". In 2000 he received the "Young Investigator Conference on Angiotensin II Award" from Merck & Co. One year later Landmesser was honored with the "Servier Young Investigator Award" of the International Symposium on Mechanisms of Vasodilatation, Boston, Mass. and the "Outstanding Fellows in Cardiology Special Recognition Award" of the Cardiology Fellows Forum of Excellence, Anaheim, California. In 2012 he received the "Frederick Goetz" price of the University of Zurich for his research on HDL cholesterol.

Memberships in scientific organisations

edit

Landmesser is deputy editor of the European Heart Journal (since 2008) and member of the Scientific Program Committee of the European Society of Cardiology (since 2010). He also is member of the working group "Interventional Cardiology and Acute Coronary Syndrome"[14] of the Swiss Society for Cardiology, board member of the group "Cardiovascular Biology Working Group" and editor of the section "Intravascular Imaging" of the scientific journal Current Cardiovascular Imaging Reports. Since 2012 he has been Treasurer and Executive Board Member of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR).[15]

Publications

edit

References

edit
  1. ^ "Charité -Cardiology Berlin - PRIMO MEDICO". Retrieved 23 November 2016.
  2. ^ Kalinowsky, Rene. "Klinik". Archived from the original on 8 October 2015. Retrieved 23 November 2016.
  3. ^ Landmesser, Ulf. "Coronary Artery Disease: HDL and Coronary Heart Disease—novel Insights." Nature Reviews Cardiology 11, no. 10 (October 2014): 559–60. doi:10.1038/nrcardio.2014.128.
  4. ^ Besler, Christian, Kathrin Heinrich, Lucia Rohrer, Carola Doerries, Meliana Riwanto, Diana M. Shih, Angeliki Chroni, et al. "Mechanisms Underlying Adverse Effects of HDL on eNOS-Activating Pathways in Patients with Coronary Artery Disease." Journal of Clinical Investigation 121, no. 7 (1 July 2011): 2693–2708. doi:10.1172/JCI42946.
  5. ^ Besler, Christian, Kathrin Heinrich, Lucia Rohrer, Carola Doerries, Meliana Riwanto, Diana M. Shih, Angeliki Chroni, et al. "Mechanisms Underlying Adverse Effects of HDL on eNOS-Activating Pathways in Patients with Coronary Artery Disease." Journal of Clinical Investigation 121, no. 7 (1 July 2011): 2693–2708. doi:10.1172/JCI42946.
  6. ^ Speer, Thimoteus, Lucia Rohrer, Przemyslaw Blyszczuk, Rukshana Shroff, Kira Kuschnerus, Nicolle Kränkel, Gabriela Kania, et al. "Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2." Immunity 38, no. 4 (18 April 2013): 754–68. doi:10.1016/j.immuni.2013.02.009.
  7. ^ Riwanto, Meliana, Lucia Rohrer, Bernd Roschitzki, Christian Besler, Pavani Mocharla, Maja Mueller, Damir Perisa, et al. "Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein-Proteome Remodeling." Circulation 127, no. 8 (26 February 2013): 891–904. doi:10.1161/CIRCULATIONAHA.112.108753.
  8. ^ Templin, Christian, Martin Meyer, Maja Franziska Müller, Valentin Djonov, Ruslan Hlushchuk, Ivanka Dimova, Stefanie Flueckiger, et al. "Coronary Optical Frequency Domain Imaging (OFDI) for in Vivo Evaluation of Stent Healing: Comparison with Light and Electron Microscopy." European Heart Journal 31, no. 14 (July 2010): 1792–1801. doi:10.1093/eurheartj/ehq168.
  9. ^ Landmesser, Ulf, and David R. Holmes. "Left Atrial Appendage Closure: A Percutaneous Transcatheter Approach for Stroke Prevention in Atrial Fibrillation." European Heart Journal 33, no. 6 (March 2012): 698–704. doi:10.1093/eurheartj/ehr393.
  10. ^ Jaguszewski, Milosz, Costantina Manes, Gilbert Puippe, Sacha Salzberg, Maja Müller, Volkmar Falk, Thomas Lüscher, Andreas Luft, Hatem Alkadhi, and Ulf Landmesser. "Cardiac CT and Echocardiographic Evaluation of Peri-Device Flow after Percutaneous Left Atrial Appendage Closure Using the AMPLATZER Cardiac Plug Device." Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography & Interventions 85, no. 2 (1 February 2015): 306–12. doi:10.1002/ccd.25667.
  11. ^ Bergmann, Martin W., and Ulf Landmesser. "Left Atrial Appendage Closure for Stroke Prevention in Non-Valvular Atrial Fibrillation: Rationale, Devices in Clinical Development and Insights into Implantation Techniques." EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 10, no. 4 (August 2014): 497–504. doi:10.4244/EIJV10I4A86.
  12. ^ Authors/Task Force members, Stephan Windecker, Philippe Kolh, Fernando Alfonso, Jean-Philippe Collet, Jochen Cremer, Volkmar Falk, et al. "2014 ESC/EACTS Guidelines on Myocardial Revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the Special Contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)." European Heart Journal 35, no. 37 (1 October 2014): 2541–2619. doi:10.1093/eurheartj/ehu278.
  13. ^ Roffi, Marco, Carlo Patrono, Jean-Philippe Collet, Christian Mueller, Marco Valgimigli, Felicita Andreotti, Jeroen J. Bax, et al. "2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)." European Heart Journal 37, no. 3 (14 January 2016): 267–315. doi:10.1093/eurheartj/ehv320.
  14. ^ babotai. "Swiss Working Group for Interventional Cardiology and Acute Coronary Syndromes". Retrieved 23 November 2016.
  15. ^ "2016-2018 EAPC Board". Retrieved 23 November 2016.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ulf_Landmesser&oldid=1118578438"